PlainRecalls
FDA Drug Moderate Class II Ongoing

Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur Dist - Dhar, Madhya Pradesh - 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-319-60.

Reported: November 15, 2023 Initiated: October 23, 2023 #D-0092-2024

Product Description

Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur Dist - Dhar, Madhya Pradesh - 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-319-60.

Reason for Recall

Failed Dissolution Specifications: Out of specification for dissolution.

Details

Units Affected
16,944 bottles
Distribution
Nationwide
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur Dist - Dhar, Madhya Pradesh - 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-319-60.. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 16,944 bottles.
Why was this product recalled?
Failed Dissolution Specifications: Out of specification for dissolution.
Which agency issued this recall?
This recall was issued by the FDA Drug on November 15, 2023. Severity: Moderate. Recall number: D-0092-2024.